PRESS-RELEASE filed Aug 13, 2026 at 16:00 ET
Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spending up 31% to $56.1M as clinical activities ramp. The stock's primary catalyst is the upcoming September 2026 DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in wet AMD, followed by December 2026 PEAK data for KSI-101 in MESI. Cash of $125.9M is expected to fund operations into 2027, but the widening loss and lack of revenue make this a binary event-driven pre-commercial biotech story.